Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin for ureteral stent-related symptoms after ureteroscopy
ACTRN12610001022055Phase 4Recruiting
- Sponsor
- Mennonite Christian Hospital
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ureteral stent-related symptoms (USRS) comparing Placebo with Solifenacin (2 arms). Primary endpoint: Improvement of ureteral stent-related symptoms. Started Oct 2010; status: recruiting.
02
Drugs
solifenacin
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on ACTRN12610001022055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001022055.